reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research
Margaret von Mehren
(ET-743) in the rat . Cancer Res 2003 ; 63 : 5902 – 5908 . 29 von Mehren M Schilder R Cheng J . Trabectedin in combination with pegylated doxorubicin (PLD) is a well tolerated regimen with good dose intensity in patients with advanced
James E. Montie, Peter E. Clark, Mario A. Eisenberger, Rizk El-Galley, Richard E. Greenberg, Harry W. Herr, Gary R. Hudes, Deborah A. Kuban, Timothy M. Kuzel, Paul H. Lange, Subodh M. Lele, Jeffrey Michalski, Anthony Patterson, Kamal S. Pohar, Jerome P. Richie, Wade J. Sexton, William U. Shipley, Eric J. Small, Donald L. Trump, Phillip J. Walther and Timothy G. Wilson
. 46 Sternberg CN de Mulder PH Schornagel JH . Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic
Yanli Li, Leila Family, Su-Jau Yang, Zandra Klippel, John H. Page and Chun Chao
. References 1. Lyman GH Dale DC Crawford J . Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices . J Clin Oncol 2003 ; 21 : 4524 – 4531 . 2. Lyman GH Kuderer NM
David D. Chism
Schornagel JH . Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors
Bin Wu and Lizheng Shi
Because the median relative dose intensity of olaparib was 99.3% (range of dose intensity, 45%–100%), 8 drug wastage cost was not assumed for olaparib in this analysis because whenever a patient with AEs needs to reduce the dose during the treatment cycle
Gregory P. Kalemkerian, Wallace Akerley, Paul Bogner, Hossein Borghaei, Laura Chow, Robert J. Downey, Leena Gandhi, Apar Kishor P. Ganti, Ramaswamy Govindan, John C. Grecula, James Hayman, Rebecca Suk Heist, Leora Horn, Thierry M. Jahan, Marianna Koczywas, Cesar A. Moran, Harvey B. Niell, Janis O'Malley, Jyoti D. Patel, Neal Ready, Charles M. Rudin and Charles C. Williams Jr.
failed to show improved PFS or overall survival with this approach. 80 , 81 Multidrug cyclic weekly therapy was designed to increase dose intensity. Early phase II results of this approach were promising, although favorable patient selection was of some
Sumanta K. Pal, Matthew I. Milowsky and Elizabeth R. Plimack
gemcitabine dose by 20% in the cetuximab arm to mitigate an observed increase in thromboembolic evens with the 3-drug combination, resulting in decreased standard-of-care dose intensity in the experimental arm. Figure 1 Relevant signaling pathways in
Peter E. Clark, Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Jason A. Efstathiou, Thomas W. Flaig, Terence Friedlander, Richard E. Greenberg, Khurshid A. Guru, Noah Hahn, Harry W. Herr, Christopher Hoimes, Brant A. Inman, A. Karim Kader, Adam S. Kibel, Timothy M. Kuzel, Subodh M. Lele, Joshua J. Meeks, Jeff Michalski, Jeffrey S. Montgomery, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Daniel Petrylak, Elizabeth R. Plimack, Kamal S. Pohar, Michael P. Porter, Wade J. Sexton, Arlene O. Siefker-Radtke, Guru Sonpavde, Jonathan Tward, Geoffrey Wile, Mary A. Dwyer and Courtney Smith
year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours . Eur J Cancer 2006 ; 42 : 50 – 54 . 36 Plimack ER Hoffman-Censits JH Viterbo R
Manish A. Shah and David P. Kelsen
. 49 An incremental improvement in overall survival was also reported in a large randomized phase II/III trial comparing DCF with CF alone. 43 Notably, although the dose intensity of cisplatin and FU was identical in both arms (cisplatin, 25 mg/m 2
